Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 733

1.

Medication Persistence and Discontinuation of Rivaroxaban and Dabigatran Etexilate among Patients with Non-Valvular Atrial Fibrillation.

Nelson WW, Song X, Thomson E, Smith DM, Coleman CI, Damaraju CV, Schein JR.

Curr Med Res Opin. 2015 Jul 27:1-31. [Epub ahead of print]

PMID:
26211816
2.

Dagibatran Etexilate: Is There Any Need for Coagulation Monitoring After Initiation?

Hoepner R, Behrendt V, Meves S, Gold R, Krogias C.

Neurologist. 2015 Jul;20(1):1-3. doi: 10.1097/NRL.0000000000000034.

PMID:
26185953
3.

Critical appraisal of dabigatran in the treatment of deep vein thrombosis and pulmonary embolism.

Ogbonna KC, Dixon DL.

J Blood Med. 2015 Jun 11;6:177-84. doi: 10.2147/JBM.S54033. eCollection 2015. Review.

4.

Perioperative Management of Antithrombotic and Antiplatelet Therapy.

Bracey AW.

Tex Heart Inst J. 2015 Jun 1;42(3):239-42. doi: 10.14503/THIJ-15-5066. eCollection 2015 Jun. No abstract available.

5.
6.

Design, Synthesis, and Biological Evaluation of Dabigatran Etexilate Mimics, a Novel Class of Thrombin Inhibitors.

Wang S, Dai P, Xu Y, Chen Q, Zhu Q, Gong G.

Arch Pharm (Weinheim). 2015 Jun 29. doi: 10.1002/ardp.201500101. [Epub ahead of print]

PMID:
26120827
7.

Dabigatran for the treatment of venous thromboembolism.

Schellong SM.

Expert Rev Hematol. 2015 Aug;8(4):413-25. doi: 10.1586/17474086.2015.1052400. Epub 2015 Jun 25.

PMID:
26111881
8.

Rationale and design of the RE-LATED AF-AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus-Effects of Dabigatran in patients with Atrial Fibrillation.

Ferner M, Wachtlin D, Konrad T, Deuster O, Meinertz T, von Bardeleben S, Münzel T, Seibert-Grafe M, Breithardt G, Rostock T.

Clin Res Cardiol. 2015 Jun 25. [Epub ahead of print]

PMID:
26109251
9.

Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives.

Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Terleira-Fernández AI, Vargas-Castrillón E.

Eur J Haematol. 2015 Jun 19. doi: 10.1111/ejh.12610. [Epub ahead of print]

PMID:
26095540
10.

Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial.

Brambatti M, Darius H, Oldgren J, Clemens A, Noack HH, Brueckmann M, Yusuf S, Wallentin L, Ezekowitz MD, Connolly SJ, Healey JS.

Int J Cardiol. 2015 Oct 1;196:127-31. doi: 10.1016/j.ijcard.2015.05.141. Epub 2015 May 28.

PMID:
26093161
11.

Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation.

Ment J.

Vasc Health Risk Manag. 2015 Jun 10;11:317-32. doi: 10.2147/VHRM.S79065. eCollection 2015. Review.

12.

Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.

Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J, Lang B, Ramael S, Moschetti V, Gruenenfelder F, Reilly P, Kreuzer J.

Lancet. 2015 Jun 15. pii: S0140-6736(15)60732-2. doi: 10.1016/S0140-6736(15)60732-2. [Epub ahead of print]

PMID:
26088268
13.

Antidotes to non-vitamin K oral anticoagulants: necessary or not?

Proietti M, Lip GY.

Expert Opin Pharmacother. 2015 Aug;16(11):1573-6. doi: 10.1517/14656566.2015.1057119. Epub 2015 Jun 16.

PMID:
26077323
14.

Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial.

Böhm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA, Schumacher H, Brueckmann M, Schirmer SH, Kratz MT, Yusuf S, Diener HC, Hijazi Z, Wallentin L.

J Am Coll Cardiol. 2015 Jun 16;65(23):2481-93. doi: 10.1016/j.jacc.2015.03.577.

PMID:
26065986
15.

Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.

Fanola CL.

Vasc Health Risk Manag. 2015 May 27;11:271-82. doi: 10.2147/VHRM.S62595. eCollection 2015. Review.

16.

Structure-guided residence time optimization of a dabigatran reversal agent.

Schiele F, van Ryn J, Litzenburger T, Ritter M, Seeliger D, Nar H.

MAbs. 2015 Jun 5:0. [Epub ahead of print]

PMID:
26047352
17.

[Use of dabigatran etexilate for treatment of deep vein thrombosis and pulmonary artery thromboembolism].

Petrikov AS, Shoikhet YN, Vyatkin DA, Zakharchenko KK, Karbyshev IA.

Angiol Sosud Khir. 2015;21(2):27-37. Russian.

PMID:
26035562
18.

The effects of dabigatran etexilate on fracture healing in rats: An experimental study.

Kerimoglu S, Onay A, Guvercin Y, Çitlak A, Yenilmez E, Kerimoglu G.

Indian J Orthop. 2015 May-Jun;49(3):357-60. doi: 10.4103/0019-5413.156227.

19.

Improved Stability of Proline-Derived Direct Thrombin Inhibitors through Hydroxyl to Heterocycle Replacement.

Chobanian HR, Pio B, Guo Y, Shen H, Huffman MA, Madeira M, Salituro G, Terebetski JL, Ormes J, Jochnowitz N, Hoos L, Zhou Y, Lewis D, Hawes B, Mitnaul L, O'Neill K, Ellsworth K, Wang L, Biftu T, Duffy JL.

ACS Med Chem Lett. 2015 Mar 13;6(5):553-7. doi: 10.1021/acsmedchemlett.5b00047. eCollection 2015 May 14.

PMID:
26005532
20.

Dose tailoring of dabigatran etexilate: obvious or excessive?

Douxfils J, Mullier F, Dogné JM.

Expert Opin Drug Saf. 2015 Aug;14(8):1283-9. doi: 10.1517/14740338.2015.1049995. Epub 2015 May 21.

PMID:
25994994
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk